{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:30:09Z","timestamp":1760722209234,"version":"build-2065373602"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"DOI":"10.7759\/cureus.94807","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:25:16Z","timestamp":1760721916000},"source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor-Engineered Natural Killer (CAR-NK) Cell Therapy in Acute Myeloid Leukemia: A Systematic Review of the Literature"],"prefix":"10.7759","author":[{"given":"Mayra Steffania","family":"Novoa Arias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil E","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al.. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016, 374:2209-21. 10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00908-z","article-title":"The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017","volume":"13","author":"Yi M","year":"2020","unstructured":"Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020, 13:72. 10.1186\/s13045-020-00908-z","journal-title":"J Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genom.3.032802.115046","article-title":"Genetics of myeloid leukemias","volume":"3","author":"Kelly LM","year":"2002","unstructured":"Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002, 3:179-98. 10.1146\/annurev.genom.3.032802.115046","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1399312","article-title":"The importance of FLT3 mutational analysis in acute myeloid leukemia","volume":"59","author":"Patnaik MM","year":"2018","unstructured":"Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2018, 59:2273-86. 10.1080\/10428194.2017.1399312","journal-title":"Leuk Lymphoma"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini B","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, et al.. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005, 352:254-66. 10.1056\/NEJMoa041974","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280802","article-title":"Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question","volume":"108","author":"Jaramillo S","year":"2023","unstructured":"Jaramillo S, Schlenk RF. Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question. Haematologica. 2023, 108:342-52. 10.3324\/haematol.2022.280802","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner H","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, et al.. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010, 115:453-74. 10.1182\/blood-2009-07-235358","journal-title":"Blood"},{"key":"ref8","unstructured":"Acute myeloid leukemia (AML) SEER relative survival rates by time since diagnosis, 2000-2021. (2024). Accessed. 5 October 2025: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=96&data_type=4&graph_type=6&compareBy=sex&c...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al.. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019, 380:45-56. 10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel J","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al.. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023, 389:335-47. 10.1056\/NEJMoa2303379","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin X","year":"2022","unstructured":"Jin X, Zhang M, Sun R, et al.. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022, 15:88. 10.1186\/s13045-022-01308-1","journal-title":"J Hematol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01708-z","article-title":"CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial","volume":"18","author":"Yin J","year":"2025","unstructured":"Yin J, Cui QY, Dai HP, et al.. CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial. J Hematol Oncol. 2025, 18:53. 10.1186\/s13045-025-01708-z","journal-title":"J Hematol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102713","article-title":"The black hole: CAR T cell therapy in AML","volume":"15","author":"Atilla E","year":"2023","unstructured":"Atilla E, Benabdellah K. The black hole: CAR T cell therapy in AML. Cancers (Basel). 2023, 15:10.3390\/cancers15102713","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori S","year":"2019","unstructured":"Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019, 16:430-41. 10.1038\/s41423-019-0206-4","journal-title":"Cell Mol Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00431-0","article-title":"Chimeric antigen receptor engineered natural killer cells for cancer therapy","volume":"12","author":"Zhang Y","year":"2023","unstructured":"Zhang Y, Zhou W, Yang J, Yang J, Wang W. Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol. 2023, 12:70. 10.1186\/s40164-023-00431-0","journal-title":"Exp Hematol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.06.025","article-title":"The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells","volume":"28","author":"Moscarelli J","year":"2022","unstructured":"Moscarelli J, Zahavi D, Maynard R, Weiner LM. The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells. Transplant Cell Ther. 2022, 28:650-6. 10.1016\/j.jtct.2022.06.025","journal-title":"Transplant Cell Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14374","article-title":"Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells","volume":"111","author":"Ueda T","year":"2020","unstructured":"Ueda T, Kumagai A, Iriguchi S, et al.. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells. Cancer Sci. 2020, 111:1478-90. 10.1111\/cas.14374","journal-title":"Cancer Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner S","year":"2017","unstructured":"Oelsner S, Friede ME, Zhang C, et al.. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017, 19:235-49. 10.1016\/j.jcyt.2016.10.009","journal-title":"Cytotherapy"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu J","year":"2014","unstructured":"Chu J, Deng Y, Benson DM, et al.. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014, 28:917-27. 10.1038\/leu.2013.279","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967956.37234.fb","article-title":"S261: first in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed\/refractory (R\/R) B-cell malignancies","volume":"7","author":"Dickinson M","year":"2023","unstructured":"Dickinson M, Hamad N, Bryant C, et al.. S261: first in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed\/refractory (R\/R) B-cell malignancies. Hemasphere. 2023, 7:e37234fb. 10.1097\/01.HS9.0000967956.37234.fb","journal-title":"Hemasphere"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans CR","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014, 14:43. 10.1186\/1471-2288-14-43","journal-title":"BMC Med Res Methodol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies","volume":"22","author":"Barker TH","year":"2024","unstructured":"Barker TH, Habibi N, Aromataris E, et al.. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth. 2024, 22:378-88. 10.11124\/JBIES-23-00268","journal-title":"JBI Evid Synth"},{"key":"ref25","unstructured":"WebPlotDigitizer - Extract data from charts. (2024). Accessed. 12 October 2025: https:\/\/automeris.io\/wpd\/."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso S","year":"2022","unstructured":"Caruso S, De Angelis B, Del Bufalo F, et al.. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022, 15:163. 10.1186\/s13045-022-01376-3","journal-title":"J Hematol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong H","year":"2022","unstructured":"Dong H, Ham JD, Hu G, et al.. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022, 119:e2122379119. 10.1073\/pnas.2122379119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref28","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang X","year":"2018","unstructured":"Tang X, Yang L, Li Z, et al.. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018, 8:1083-9.","journal-title":"Am J Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger N","year":"2022","unstructured":"Albinger N, Pfeifer R, Nitsche M, et al.. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 2022, 12:61. 10.1038\/s41408-022-00660-2","journal-title":"Blood Cancer J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02180-4","article-title":"Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia","volume":"59","author":"Albinger N","year":"2024","unstructured":"Albinger N, M\u00fcller S, Kostyra J, et al.. Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia. Bone Marrow Transplant. 2024, 59:489-95. 10.1038\/s41409-023-02180-4","journal-title":"Bone Marrow Transplant"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou I","year":"2021","unstructured":"Christodoulou I, Ho WJ, Marple A, et al.. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-003894","journal-title":"J Immunother Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in\u00a0vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du Z","year":"2021","unstructured":"Du Z, Ng YY, Zha S, Wang S. piggyBac system to co-express NKG2D CAR and IL-15 to augment the in\u00a0vivo persistence and anti-AML activity of human peripheral blood NK cells. Mol Ther Methods Clin Dev. 2021, 23:582-96. 10.1016\/j.omtm.2021.10.014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007405","article-title":"Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia","volume":"7","author":"Mansour AG","year":"2023","unstructured":"Mansour AG, Teng KY, Li Z, et al.. Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia. Blood Adv. 2023, 7:6225-39. 10.1182\/bloodadvances.2022007405","journal-title":"Blood Adv"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/v13071365","article-title":"Improved activity against acute myeloid leukemia with chimeric antigen receptor (CAR)-NK-92 cells designed to target CD123","volume":"13","author":"Morgan MA","year":"2021","unstructured":"Morgan MA, Kloos A, Lenz D, et al.. Improved activity against acute myeloid leukemia with chimeric antigen receptor (CAR)-NK-92 cells designed to target CD123. Viruses. 2021, 13:10.3390\/v13071365","journal-title":"Viruses"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.7150\/jca.28952","article-title":"Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T cells and NK cells","volume":"10","author":"Salman H","year":"2019","unstructured":"Salman H, Pinz KG, Wada M, Shuai X, Yan LE, Petrov JC, Ma Y. Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T cells and NK cells. J Cancer. 2019, 10:4408-19. 10.7150\/jca.28952","journal-title":"J Cancer"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216103","article-title":"Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia","volume":"558","author":"Zhang R","year":"2023","unstructured":"Zhang R, Liu Q, Zhou S, He H, Zhao M, Ma W. Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia. Cancer Lett. 2023, 558:216103. 10.1016\/j.canlet.2023.216103","journal-title":"Cancer Lett"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.06.003","article-title":"Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19(+) malignancy in a mouse model","volume":"22","author":"Liu Q","year":"2020","unstructured":"Liu Q, Xu Y, Mou J, et al.. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19(+) malignancy in a mouse model. Cytotherapy. 2020, 22:552-62. 10.1016\/j.jcyt.2020.06.003","journal-title":"Cytotherapy"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03350-6","article-title":"Optimizing NK-92 serial killers: gamma irradiation, CD95\/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy","volume":"20","author":"Navarrete-Galvan L","year":"2022","unstructured":"Navarrete-Galvan L, Guglielmo M, Cruz Amaya J, Smith-Gagen J, Lombardi VC, Merica R, Hudig D. Optimizing NK-92 serial killers: gamma irradiation, CD95\/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy. J Transl Med. 2022, 20:151. 10.1186\/s12967-022-03350-6","journal-title":"J Transl Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina S","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, et al.. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008, 118:3132-42. 10.1172\/JCI35700","journal-title":"J Clin Invest"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.59","article-title":"Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia","volume":"20","author":"Heckl D","year":"2012","unstructured":"Heckl D, Schwarzer A, Haemmerle R, et al.. Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia. Mol Ther. 2012, 20:1187-95. 10.1038\/mt.2012.59","journal-title":"Mol Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000072","article-title":"Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor","volume":"38","author":"Wang X","year":"2015","unstructured":"Wang X, Olszewska M, Qu J, et al.. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor. J Immunother. 2015, 38:127-35. 10.1097\/CJI.0000000000000072","journal-title":"J Immunother"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani CF","year":"2020","unstructured":"Magnani CF, Gaipa G, Lussana F, et al.. Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Invest. 2020, 130:6021-33. 10.1172\/JCI138473","journal-title":"J Clin Invest"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.03.003","article-title":"Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy","volume":"29","author":"Imre G","year":"2023","unstructured":"Imre G, Tak\u00e1cs B, Czipa E, et al.. Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy. Mol Ther Methods Clin Dev. 2023, 29:145-59. 10.1016\/j.omtm.2023.03.003","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-2-17","article-title":"Forecasting the cytokine storm following systemic interleukin (IL)-2 administration","volume":"2","author":"Panelli MC","year":"2004","unstructured":"Panelli MC, White R, Foster M, Martin B, Wang E, Smith K, Marincola FM. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med. 2004, 2:17. 10.1186\/1479-5876-2-17","journal-title":"J Transl Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein R","year":"2018","unstructured":"Ladenstein R, P\u00f6tschger U, Valteau-Couanet D, et al.. Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018, 19:1617-29. 10.1016\/S1470-2045(18)30578-3","journal-title":"Lancet Oncol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children","volume":"3","author":"Whangbo JS","year":"2019","unstructured":"Whangbo JS, Kim HT, Mirkovic N, et al.. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019, 3:2550-61. 10.1182\/bloodadvances.2019000631","journal-title":"Blood Adv"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann TA","year":"2006","unstructured":"Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006, 6:595-601. 10.1038\/nri1901","journal-title":"Nat Rev Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion","volume":"25","author":"Conlon KC","year":"2019","unstructured":"Conlon KC, Potter EL, Pittaluga S, et al.. IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion. Clin Cancer Res. 2019, 25:4945-54. 10.1158\/1078-0432.CCR-18-3468","journal-title":"Clin Cancer Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices M","year":"2018","unstructured":"Felices M, Lenvik AJ, McElmurry R, et al.. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight. 2018, 3:10.1172\/jci.insight.96219","journal-title":"JCI Insight"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030577","article-title":"Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy","volume":"13","author":"Fern\u00e1ndez A","year":"2021","unstructured":"Fern\u00e1ndez A, Navarro-Zapata A, Escudero A, et al.. Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy. Cancers (Basel). 2021, 13:10.3390\/cancers13030577","journal-title":"Cancers (Basel)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3684-7_29","article-title":"Regulatory considerations for NK cells used in human immunotherapy applications","author":"Lee DA","year":"2016","unstructured":"Lee DA. Regulatory considerations for NK cells used in human immunotherapy applications. Methods Mol Biol. 2016. 1441:347-61. 10.1007\/978-1-4939-3684-7_29"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu E","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, et al.. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018, 32:520-31. 10.1038\/leu.2017.226","journal-title":"Leukemia"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-556837","article-title":"Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15","volume":"124","author":"Imamura M","year":"2014","unstructured":"Imamura M, Shook D, Kamiya T, et al.. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood. 2014, 124:1081-8. 10.1182\/blood-2014-02-556837","journal-title":"Blood"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee R","year":"2012","unstructured":"Romee R, Schneider SE, Leong JW, et al.. Cytokine activation induces human memory-like NK cells. Blood. 2012, 120:4751-60. 10.1182\/blood-2012-04-419283","journal-title":"Blood"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski JJ","year":"2022","unstructured":"Bednarski JJ, Zimmerman C, Berrien-Elliott MM, et al.. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood. 2022, 139:1670-83. 10.1182\/blood.2021013972","journal-title":"Blood"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01302-6","article-title":"Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia","volume":"20","author":"Dai YJ","year":"2021","unstructured":"Dai YJ, He SY, Hu F, et al.. Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia. Mol Cancer. 2021, 20:8. 10.1186\/s12943-020-01302-6","journal-title":"Mol Cancer"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02028","article-title":"Highly efficient generation of transgenically augmented CAR NK cells overexpressing CXCR4","volume":"11","author":"Jamali A","year":"2020","unstructured":"Jamali A, Hadjati J, Madjd Z, et al.. Highly efficient generation of transgenically augmented CAR NK cells overexpressing CXCR4. Front Immunol. 2020, 11:2028. 10.3389\/fimmu.2020.02028","journal-title":"Front Immunol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091358","article-title":"CD123 as a therapeutic target in the treatment of hematological malignancies","volume":"11","author":"Testa U","year":"2019","unstructured":"Testa U, Pelosi E, Castelli G. CD123 as a therapeutic target in the treatment of hematological malignancies. Cancers (Basel). 2019, 11:10.3390\/cancers11091358","journal-title":"Cancers (Basel)"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgae184","article-title":"Nanobody-based CAR NK cells for possible immunotherapy of MICA(+) tumors","volume":"3","author":"Verhaar ER","year":"2024","unstructured":"Verhaar ER, van Keizerswaard WJ, Knoflook A, Balligand T, Ploegh HL. Nanobody-based CAR NK cells for possible immunotherapy of MICA(+) tumors. PNAS Nexus. 2024, 3:pgae184. 10.1093\/pnasnexus\/pgae184","journal-title":"PNAS Nexus"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.03.006","article-title":"Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles","volume":"29","author":"Jo DH","year":"2023","unstructured":"Jo DH, Kaczmarek S, Shin O, Wang L, Cowan J, McComb S, Lee SH. Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles. Mol Ther Methods Clin Dev. 2023, 29:173-84. 10.1016\/j.omtm.2023.03.006","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1825177","article-title":"Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting","volume":"9","author":"Grote S","year":"2020","unstructured":"Grote S, Mittelstaet J, Baden C, et al.. Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. Oncoimmunology. 2020, 9:1825177. 10.1080\/2162402X.2020.1825177","journal-title":"Oncoimmunology"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755639","article-title":"Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies","volume":"12","author":"Guercio M","year":"2021","unstructured":"Guercio M, Manni S, Boffa I, et al.. Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies. Front Immunol. 2021, 12:755639. 10.3389\/fimmu.2021.755639","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/419759-chimeric-antigen-receptor-engineered-natural-killer-car-nk-cell-therapy-in-acute-myeloid-leukemia-a-systematic-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:25:18Z","timestamp":1760721918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/419759-chimeric-antigen-receptor-engineered-natural-killer-car-nk-cell-therapy-in-acute-myeloid-leukemia-a-systematic-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":62,"URL":"https:\/\/doi.org\/10.7759\/cureus.94807","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}